Stock Details
AMGN is Amgen Inc.'s stock. Stock exchange NasdaqGS (Currency USD). Average price in 50 days is 239.82$. Average daily volumn in 3 months 2.55M. Market cap 122.52B



Stock symbol : AMGN. Exchange : NasdaqGS. Currency : USD
Lastest price : 229.03$. Total volume : 2.06M. Market state POST
Click reload if you want to check the lastest price on market!!!

Amgen Inc. (AMGN)
Last Price
229.03$
Change
-1.91
Volume
2.06M

Previous Close230.94
Open230.00
Day Range228.58-231.51
Bid228.12 x 800
Ask229.67 x 800
Volume2.06M
Average Volume2.55M
Market Cap122.52B
Beta0.58
52 Week Range198.64-258.45
Trailing P/E19.48
Foward P/E12.25
Dividend (Yield %)3.32%
Ex-Dividend Date2022-08-17



Financial Details


According to Amgen Inc.'s financial reports the company's revenue in 2021 were 25.98B an increase(0%) over the years 2020 revenue that were of 25.42B. In 2021 the company's total earnings were 5.89B while total earnings in 2020 were 7.26B(-28.57%).


Loading ...



Organization

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-rel... ated events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behรงet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Market Cap:
122.52B
Revenue:
25.98B
Total Assets:
61.16B
Total Cash:
7.99B


News about "Amgen Inc."

amgens-short-big-move-designed-to-execute-at-corner-of-tech-and-biotech-image

Amgen's short, big move designed to execute at corner of tech and biotech

Source from : The Business Journals - 1 days ago

Since Amgen (NASDAQ: AMGN) set up its South San Francisco facility in 2004, a lot has changed. California fire codes, for one, have allowed biotech companies to move into tall buildings like those ...See details»


us-government-buys-radiation-sickness-drug-as-part-of-long-standing-program-image

US government buys radiation sickness drug as part of long-standing program

Source from : St. Louis Post-Dispatch - 11 hours ago

Concerns about potential use of nuclear weapons have risen after Russian President Vladimir Putin has issued warnings in recent weeks.See details»


biden-admin-stockpiling-for-nuclear-armageddon-on-american-soil-hhs-290m-purchase-may-be-dead-giveaway-image

Biden Admin Stockpiling for Nuclear Armageddon on American Soil? HHS $290M Purchase May Be Dead Giveaway

Source from : ijr.com - 18 hours ago

the U.S. Department of Health and Human Services is purchasing a supply of the drug Nplate from Amgen USA Inc,โ€ the Administration for Strategic Preparedness and Response stated in the release.See details»


us-purchases-290-million-of-drug-for-use-in-radiological-and-nuclear-emergencies-image

US purchases $290 million of drug for use in radiological and nuclear emergencies

Source from : The Hill on MSN - 1 days ago

The Department of Health and Human Services (HHS) says it has spent $290 million on a drug to treat radiation sickness in the event of a nuclear emergency. The HHS Administration for ...See details»


Amgen Inc. (NASDAQ:AMGN) Looks Just Right

Source from : Yahoo Finance - 6 days ago

With a price-to-earnings (or "P/E") ratio of 18.3x Amgen Inc. (NASDAQ:AMGN) may be sending bearish signals at the moment, given that almost half of all companies in the United States have P/E ...See details»


amgen-nasdaqamgn-receives-outperform-rating-from-oppenheimer-image

Amgen (NASDAQ:AMGN) Receives โ€œOutperformโ€ Rating from Oppenheimer

Source from : Defense World - 3 days ago

Oppenheimer reiterated their outperform rating on shares of Amgen (NASDAQ:AMGN โ€“ Get Rating) in a report issued on Monday. Oppenheimer currently has a $290.00 price objective on the medical research ...See details»


moderna-inc-stock-underperforms-friday-when-compared-to-competitors-image

Moderna Inc. stock underperforms Friday when compared to competitors

Source from : MarketWatch on MSN - 9 hours ago

Shares of Moderna Inc. slipped 4.66% to $119.32 Friday, on what proved to be an all-around dismal trading session for the stock market, with the NASDAQ Composite Index falling 3.80% to 10,652.40 and ...See details»


miracle-mile-advisors-llc-grows-position-in-amgen-inc-nasdaqamgn-image

Miracle Mile Advisors LLC Grows Position in Amgen Inc. (NASDAQ:AMGN)

Source from : Defense World - 12 days ago

Miracle Mile Advisors LLC increased its holdings in Amgen Inc. (NASDAQ:AMGN โ€“ Get Rating) by 181.0% in the second quarter, according to the company in its most recent disclosure with the Securities ...See details»


amgen-nasdaqamgn-jumps-31-this-week-though-earnings-growth-is-still-tracking-behind-five-year-shareholder-returns-image

Amgen (NASDAQ:AMGN) jumps 3.1% this week, though earnings growth is still tracking behind five-year shareholder returns

Source from : Yahoo Finance - 2 days ago

The past week has proven to be lucrative for Amgen investors, so let's see if fundamentals drove the company's five-year performance. To paraphrase Benjamin Graham: Over the short term the market is a ...See details»


Thursday Digest: Uber inks self-driving taxi deal; Biotech opens huge new lab

Source from : The Business Journals - 1 days ago

Thousand Oaks-based biotech Amgen (Nasdaq: AMGN) announced Thursday the opening of its new research and development site in South San Francisco's Oyster Point. The new site will be the company's ...See details»


moderna-inc-stock-outperforms-competitors-despite-losses-on-the-day-image

Moderna Inc. stock outperforms competitors despite losses on the day

Source from : MarketWatch on MSN - 1 days ago

Shares of Moderna Inc. slipped 0.37% to $125.15 Thursday, on what proved to be an all-around dismal trading session for the stock market, with the NASDAQ Composite Index falling 0.68% to 11,073.31 and ...See details»


Review Not Warranted: SG Tells SCOTUS to Scrap Amgenโ€™s Case on Enablement Test for Biotech Patents

Source from : IPWatchdog - 12 days ago

and Biogen Inc., Bristol-Myers Squibb Company, Corning Incorporated, and Merck Sharp & Dohme Corp. filed amicus briefs in the CAFC case. Amgen argued that the CAFC โ€œcreated a new test for ...See details»


Amgen Inc. (NASDAQ:AMGN) insiders sold US$4.9m worth of stock suggesting impending weakness.

Source from : Yahoo Finance - 10 days ago

Many Amgen Inc. (NASDAQ:AMGN) insiders ditched their stock over the past year, which may be of interest to the company's shareholders. Knowing whether insiders are buying is usually more helpful when ...See details»


Monday's Top Analyst Upgrades and Downgrades: Amgen, CrowdStrike, Intuit, Micron Technology, Microsoft, Nike, Roblox, Wells Fargo and More

Source from : 24/7 Wall St - 4 days ago

Amgen Inc. (NASDAQ: AMGN): Oppenheimer maintained an Outperform rating on the legacy biotech giant with a $290 price target. The consensus target is $253.12. The stock closed on Friday at $225.40.See details»